Fedha

Hisa unazofuatilia
Kwa nini MANKIND imepungua kwa 3.07%?
Fahamu zaidi
MANKIND:NSE
Mankind Pharma Ltd
₹ 2,275.50
-3.07%
(-72.10) Siku 1
16 Okt, 15:30:00 GMT +5:30  ·   INR
Alama zote
AlamaBeiTofautiTofauti ya asilimia
Inatayarisha maarifa maarufu ya MANKIND...
Fungua
₹ 2,349.90
Juu
₹ 2,354.40
Chini
₹ 2,268.70
Mtaji wa soko
937.40B
Wastani wa kiasi cha mauzo
elfu 483.95
Kiasi cha mauzo ya hisa
elfu 889.73
Uwiano wa bei ya hisa na mapato kwa kila hisa
46.04
Juu kwa wiki 52
₹ 2,642.00
Chini kwa wiki 52
₹ 1,909.70
EPS
₹ 49.42
Idadi ya wafanyakazi
elfu 20
Fungua
₹ 2,349.90
Juu
₹ 2,354.40
Chini
₹ 2,268.70
Mtaji wa soko
937.40B
Wastani wa kiasi cha mauzo
elfu 483.95
Kiasi cha mauzo ya hisa
elfu 889.73
Uwiano wa bei ya hisa na mapato kwa kila hisa
46.04
Juu kwa wiki 52
₹ 2,642.00
Chini kwa wiki 52
₹ 1,909.70
EPS
₹ 49.42
Idadi ya wafanyakazi
elfu 20
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Wasifu
Mankind Pharma is an Indian multinational pharmaceutical and healthcare product company, headquartered in Delhi. The company has products in therapeutic areas ranging from antibiotics, to gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications. As of 2023, Mankind Pharma had 25 factories and 6 R&D centres in India. The company derived 97% of its operating revenue from the Indian market, where it is reportedly the fourth largest pharmaceutical company by domestic sales. Some of Mankind Pharma's consumer healthcare brands are the largest-selling in their respective categories, including Manforce in condoms, Prega News in pregnancy test kits, and Unwanted-72 in emergency contraception. Wikipedia
Kuhusu Mankind Pharma Ltd
Afisa Mkuu Mtendaji (CEO)Rajeev Juneja | Sheetal Arora
Wafanyakazielfu 20.5
Lilianzishwa1991
Makao makuu-
Sekta-
Tovutimankindpharma.com
Simu inayofuata baada ya siku baada ya siku 8
Jumatatu, 26 Okt, 14:30
Kipindi cha Kifedha
Robo2 2027
- / ₹ 14.77
Mapato dhidi ya makadirio (INR)
- / 41.66B
Mkutano pepe wa kujadili mapato ya robo ya Robo ya 2 ya mwaka wa fedha wa 2027
Inasubiri mkutano pepe wa kujadili mapato
Kwa muhtasari: mapato yajayo
Maarifa kutoka kwenye ripoti na habari za hivi punde
Ripoti za awaliThamani zote katika INR
Loading Previous Earnings...
Mapato
Mapato halisi
Thamani zote katika INR
Sep 2025
Des 2025
Mac 2026
Jun 2026
Mapato
36.97B
35.67B
34.43B
40.31B
Gharama ya bidhaa zilizouzwa
10.62B
9.78B
11.71B
10.98B
Gharama ya mapato
10.62B
9.78B
11.71B
10.98B
Gharama za utafiti na maendeleo
-
-
-
-
Jumla ya gharama za utafiti na maendeleo
-
-
-
-
Gharama za uuzaji, za jumla na za usimamizi
8.25B
8.24B
15.80B
9.14B
Gharama ya uendeshaji
19.35B
18.92B
14.77B
21.02B
Jumla ya gharama za uendeshaji
29.98B
28.70B
26.48B
32.00B
Mapato ya uendeshaji
7.00B
6.97B
7.95B
8.30B
Mapato mengine yasiyo ya uendeshaji
918.70M
727.50M
-2.31B
450.00M
EBT ikijumuisha vipengee visivyo vya kawaida
6.24B
5.09B
6.59B
7.69B
EBT bila kujumuisha vipengee visivyo vya kawaida
6.24B
6.16B
5.59B
7.69B
Gharama ya kodi ya mapato
1.04B
951.20M
997.50M
1.95B
Kiwango cha kodi kinachotumika
16.64%
18.69%
15.13%
25.39%
Gharama nyingine za uendeshaji
8.88B
8.46B
-3.26B
9.63B
Mapato halisi
5.12B
4.09B
5.54B
5.68B
Kiwango cha faida halisi
13.84%
11.46%
16.10%
14.09%
Mapato kwa kila hisa
12.38
11.99
13.89
13.74
Mapato ya riba na uwekezaji
-
-
580.50M
-
Gharama ya riba
-1.70B
-1.57B
-1.36B
-1.10B
Jumla ya gharama halisi za riba
-1.70B
-1.57B
-778.20M
-1.10B
Gharama za kushuka kwa thamani na za kulipa deni
2.22B
2.23B
2.23B
2.26B
Mapato ya kampuni kabla ya riba, kodi, kushuka thamani na kulipa madeni
9.20B
8.42B
9.97B
10.33B
Faida au hasara kutokana na uuzaji wa vipengee
-
-
-
-
Maudhui yaliyotayarishwa kwa AI yanaweza kuwa na makosa. Pata maelezo zaidi
UsaidiziTuma maoniFaraghaSheria na MashartiKanusho
Programu za Google